Literature DB >> 15625601

[Bullous drug reactions].

M S Hertl-Yazdi1, M Hertl.   

Abstract

Bullous drug exanthems are clinically characteristic, usually severe cutaneous and mucosal drug hypersensitivity reactions. Commonly, they appear 5-14 days after onset of drug treatment. Therapy of choice is to avoid the culprit drug and systemic administration of glucocorticoids. A key element in the immune pathogenesis of bullous drug exanthems is presumably the activation of cytotoxic CD8(+) T lymphocytes which recognize drug metabolites as nominal antigens. These compounds form spontaneously (e.g. penicillins) or are metabolized by cytochrome P450-dependent enzymes (sulfonamides). The diagnosis of bullous drug exanthems is primarily based on skin tests and in vitro-techniques. Among the skin tests, prick as well as patch tests are important. Patch tests can be also applied at the former skin lesion in fixed drug eruption. In vitro techniques include analysis of drug-specific IgE (only available for anti-penicillin, anti-sulfamethoxazole) and cellular tests with the patients' lymphocytes (lymphocyte transformation test-LTT).

Entities:  

Mesh:

Year:  2005        PMID: 15625601     DOI: 10.1007/s00105-004-0873-6

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  23 in total

1.  Recognition of pemphigus antigens in drug-induced pemphigus vulgaris and pemphigus foliaceus.

Authors:  S Brenner; A Bialy-Golan; G J Anhalt
Journal:  J Am Acad Dermatol       Date:  1997-06       Impact factor: 11.527

2.  Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells.

Authors:  Amal Nassif; Armand Bensussan; Laurence Boumsell; Aurelien Deniaud; Homayoun Moslehi; Pierre Wolkenstein; Martine Bagot; Jean-Claude Roujeau
Journal:  J Allergy Clin Immunol       Date:  2004-11       Impact factor: 10.793

Review 3.  Molecular features of penicillin allergy.

Authors:  H U Weltzien; E Padovan
Journal:  J Invest Dermatol       Date:  1998-03       Impact factor: 8.551

Review 4.  Vancomycin-induced linear IgA bullous disease presenting as toxic epidermal necrolysis.

Authors:  M A Waldman; D R Black; J P Callen
Journal:  Clin Exp Dermatol       Date:  2004-11       Impact factor: 3.470

5.  Transepidermal induction of contact hypersensitivity in mice with a water-soluble hapten.

Authors:  T Shimizu; C G Munn; J W Streilein
Journal:  J Invest Dermatol       Date:  1993-11       Impact factor: 8.551

6.  The culprit drugs in 87 cases of toxic epidermal necrolysis (Lyell's syndrome).

Authors:  J C Guillaume; J C Roujeau; J Revuz; D Penso; R Touraine
Journal:  Arch Dermatol       Date:  1987-09

7.  Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin.

Authors:  I Viard; P Wehrli; R Bullani; P Schneider; N Holler; D Salomon; T Hunziker; J H Saurat; J Tschopp; L E French
Journal:  Science       Date:  1998-10-16       Impact factor: 47.728

8.  CD8+ dermal T cells from a sulphamethoxazole-induced bullous exanthem proliferate in response to drug-modified liver microsomes.

Authors:  M Hertl; F Jugert; H F Merk
Journal:  Br J Dermatol       Date:  1995-02       Impact factor: 9.302

Review 9.  Drug-induced linear IgA bullous dermatosis: report of six cases and review of the literature.

Authors:  M K Kuechle; E Stegemeir; B Maynard; L E Gibson; K M Leiferman; M S Peters
Journal:  J Am Acad Dermatol       Date:  1994-02       Impact factor: 11.527

10.  Autoantibodies to desmoplakin I and II in patients with erythema multiforme.

Authors:  D Foedinger; G J Anhalt; B Boecskoer; A Elbe; K Wolff; K Rappersberger
Journal:  J Exp Med       Date:  1995-01-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.